Cargando…

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

Strong evidence has accumulated on the prognostic value of tumour-associated proteolytic factors in patients afflicted with solid malignant tumours, including advanced ovarian cancer. We evaluated the prognostic impact of the protease urokinase plasminogen activator (uPA) and its inhibitor PAI-1 on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuhn, W, Schmalfeldt, B, Reuning, U, Pache, L, Berger, U, Ulm, K, Harbeck, N, Späthe, K, Dettmar, P, Höfler, H, Jänicke, F, Schmitt, M, Graeff, H
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362775/ https://www.ncbi.nlm.nih.gov/pubmed/10206287 http://dx.doi.org/10.1038/sj.bjc.6690278

Ejemplares similares

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
por: Schmitt, M., et al.
Publicado: (1997)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
por: Harbeck, N, et al.
Publicado: (1999)

Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
por: Märkl, Bruno, et al.
Publicado: (2019)

Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves
por: Kochtebane, Najlah, et al.
Publicado: (2014)

uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
por: Duffy, Michael J, et al.
Publicado: (2014)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)
por: Torres-Paris, Constanza, et al.
Publicado: (2023)

Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
por: Cunningham, Orla, et al.
Publicado: (2009)

Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer
por: Pusina, Sadat
Publicado: (2018)

Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer
por: Asuthkar, Swapna, et al.
Publicado: (2013)

Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
por: Micalet, Auxtine, et al.
Publicado: (2023)

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
por: de Witte, J H, et al.
Publicado: (1999)

Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA
por: Dreymann, Nico, et al.
Publicado: (2022)

Tumor Budding, uPA, and PAI-1 in Colorectal Cancer: Update of a Prospective Study
por: Märkl, Bruno, et al.
Publicado: (2017)

uPA‐PAI‐1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils
por: Uhl, Bernd, et al.
Publicado: (2021)

A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection
por: Sanderson-Smith, Martina L., et al.
Publicado: (2013)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
por: Sweep, C. G., et al.
Publicado: (1998)

Inhibition of urokinase plasminogen activator “uPA” activity alters ethanol consumption and conditioned place preference in mice
por: Al Maamari, Elyazia, et al.
Publicado: (2014)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers
por: Deluche, Elise, et al.
Publicado: (2017)

TEM8 functions as a receptor for uPA and mediates uPA-stimulated EGFR phosphorylation
por: Zhang, Lian-Cheng, et al.
Publicado: (2018)

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
por: Ettl, Johannes, et al.
Publicado: (2017)

The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity
por: Cochran, Blake J, et al.
Publicado: (2009)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

Upregulation of P2Y(2)R, Active uPA, and PAI-1 Are Essential Components of Hantavirus Cardiopulmonary Syndrome
por: Bondu, Virginie, et al.
Publicado: (2018)

Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
por: Chang, Hong, et al.
Publicado: (2023)

Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors
por: Ye, Yanna, et al.
Publicado: (2023)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)

A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures
por: Gibbs, John F., et al.
Publicado: (2009)

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
por: Santos, Nancy Dos, et al.
Publicado: (2007)

Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array
por: Völker, Hans-Ullrich, et al.
Publicado: (2018)

Construction of a Single Lentiviral Vector Containing Tetracycline-Inducible Alb-uPA for Transduction of uPA Expression in Murine Hepatocytes
por: Bai, Jiasi, et al.
Publicado: (2013)

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
por: Qin, Fengying, et al.
Publicado: (2022)

Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer
por: Long, Xingtao, et al.
Publicado: (2023)

uPA-mediated plasminogen activation is enhanced by polyphosphate
por: Whyte, Claire S., et al.
Publicado: (2020)

uPA dependent and independent mechanisms of wound healing by C-phycocyanin
por: Madhyastha, H K, et al.
Publicado: (2008)

A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System
por: Liu, Xiaoliang, et al.
Publicado: (2020)

Discussion on the rationality of FIGO 2018 stage IIIC for cervical cancer with oncological outcomes: a cohort study
por: Li, Zhiqiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uo5s2kt9oibp8gqhji7jgg9572